JP2017523178A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523178A5 JP2017523178A5 JP2017504104A JP2017504104A JP2017523178A5 JP 2017523178 A5 JP2017523178 A5 JP 2017523178A5 JP 2017504104 A JP2017504104 A JP 2017504104A JP 2017504104 A JP2017504104 A JP 2017504104A JP 2017523178 A5 JP2017523178 A5 JP 2017523178A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mds
- alkyl
- use according
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(C1[C@@](CC2)O[C@@]2C1C(N1CC*CC1)=O)=O Chemical compound *C(C1[C@@](CC2)O[C@@]2C1C(N1CC*CC1)=O)=O 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462028729P | 2014-07-24 | 2014-07-24 | |
| US62/028,729 | 2014-07-24 | ||
| US201462029327P | 2014-07-25 | 2014-07-25 | |
| US62/029,327 | 2014-07-25 | ||
| PCT/US2015/041714 WO2016014783A1 (en) | 2014-07-24 | 2015-07-23 | Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232414A Division JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523178A JP2017523178A (ja) | 2017-08-17 |
| JP2017523178A5 true JP2017523178A5 (cg-RX-API-DMAC7.html) | 2018-08-30 |
| JP6453441B2 JP6453441B2 (ja) | 2019-01-16 |
Family
ID=55163749
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017504104A Expired - Fee Related JP6453441B2 (ja) | 2014-07-24 | 2015-07-23 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
| JP2018232414A Expired - Fee Related JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018232414A Expired - Fee Related JP6862404B2 (ja) | 2014-07-24 | 2018-12-12 | 骨髄異形成症候群を治療するためのタンパク質ホスファターゼ２ａ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10071094B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3171870B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6453441B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106572989B (cg-RX-API-DMAC7.html) |
| WO (2) | WO2016014783A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| EP2867239A4 (en) | 2012-06-29 | 2015-12-23 | Lixte Biotechnology Inc | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES |
| WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| US10071094B2 (en) | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| AU2016219853B2 (en) | 2015-02-19 | 2019-05-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
| MX393461B (es) | 2015-05-15 | 2025-03-24 | Lixte Biotechnology Inc | Farmacos precursores de oxabicicloheptanos |
| JP6964593B2 (ja) * | 2016-01-27 | 2021-11-10 | リクスト・バイオテクノロジー，インコーポレイテッド | ホスファターゼ阻害剤を使用して骨髄異形成症候群を処置するための臨床レジメン |
| US12168008B2 (en) | 2016-12-08 | 2024-12-17 | Lixte Biotechnology, Inc. | Oxabicycloheptanes for modulation of immune response |
| CN113694071B (zh) * | 2021-08-31 | 2025-08-15 | 上海交通大学医学院附属瑞金医院 | 清除和/或溶解衰老细胞和/或抑制细胞衰老的化合物用于治疗精神障碍 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| WO2006052842A2 (en) | 2004-11-09 | 2006-05-18 | The Trustees Of The University Of Pennsylvania | Methods for diagnosis of myelodysplastic syndromes (mds) |
| EP1986619A4 (en) | 2006-02-06 | 2010-04-28 | Lixte Biotechnology Inc | USE OF PHOSPHATASES FOR THE TREATMENT OF TUMORS BY N-COR OVEREXPRESSION |
| TWI449524B (zh) * | 2006-09-07 | 2014-08-21 | Stemline Therapeutics Inc | 以斑螫酸酐（ｃａｎｔｈａｒｉｄｉｎ）及斑螫酸酐類似物進行之癌症治療 |
| US7998957B2 (en) | 2007-02-06 | 2011-08-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use |
| CA2718472A1 (en) | 2007-08-03 | 2009-02-12 | Lixte Biotechnology, Inc. | Use of phosphatases to treat neuroblastomas and medulloblastomas |
| ES2628748T3 (es) | 2007-10-01 | 2017-08-03 | Lixte Biotechnology, Inc. | Inhibidores de la HDAC |
| WO2010014220A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| WO2010014141A1 (en) | 2008-08-01 | 2010-02-04 | Lixte Biotechnology, Inc. | Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
| US8227473B2 (en) | 2008-08-01 | 2012-07-24 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use |
| WO2010147612A1 (en) | 2009-06-18 | 2010-12-23 | Lixte Biotechnology, Inc. | Methods of modulating cell regulation by inhibiting p53 |
| US20120135522A1 (en) | 2009-06-18 | 2012-05-31 | Kovach John S | Methods of modulating cell regulation by inhibiting p53 |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| US20140235649A1 (en) | 2011-05-24 | 2014-08-21 | Lixte Biotechnology, Inc. | Use of phosphatase inhibitors or histone deacetylase inhibitors to treat diseases characterized by loss of protein function |
| WO2013056211A2 (en) * | 2011-10-13 | 2013-04-18 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Telomerase reverse transcriptase deficience as diagnostic marker of myelodysplastic syndrome |
| EP2867239A4 (en) | 2012-06-29 | 2015-12-23 | Lixte Biotechnology Inc | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES |
| EP2870161B1 (en) | 2012-06-29 | 2018-08-08 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of reperfusion injury |
| US9738933B2 (en) * | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
| EP2964026A4 (en) | 2013-03-05 | 2016-08-17 | Lixte Biotechnology Inc | HDAC INHIBITORS FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY |
| US20160009727A1 (en) | 2013-03-15 | 2016-01-14 | Lixte Biotechnology, Inc. | Sanguinarine analog pp2c inhibitors for cancer treatment |
| WO2014168941A1 (en) | 2013-04-09 | 2014-10-16 | Lixte Biotechnology, Inc. | Formulations of oxabicycloheptanes and oxabicycloheptenes |
| WO2015073802A1 (en) | 2013-11-15 | 2015-05-21 | Lixte Biotechnology, Inc. | Protein phosphatase inhibitors that cross the blood brain barrier |
| US20170136008A1 (en) | 2014-06-20 | 2017-05-18 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer |
| US10071094B2 (en) * | 2014-07-24 | 2018-09-11 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes |
| CN107072991A (zh) | 2014-09-12 | 2017-08-18 | 莱克斯特生物技术公司 | 磷酸酶抑制剂的人类给药 |
| WO2016061193A1 (en) | 2014-10-15 | 2016-04-21 | Lixte Biotechnology, Inc. | Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid |
| AU2016219853B2 (en) | 2015-02-19 | 2019-05-16 | Lixte Biotechnology, Inc. | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders |
| MX393461B (es) | 2015-05-15 | 2025-03-24 | Lixte Biotechnology Inc | Farmacos precursores de oxabicicloheptanos |
-
2015
- 2015-07-23 US US15/328,235 patent/US10071094B2/en active Active
- 2015-07-23 WO PCT/US2015/041714 patent/WO2016014783A1/en not_active Ceased
- 2015-07-23 CN CN201580041767.1A patent/CN106572989B/zh not_active Expired - Fee Related
- 2015-07-23 WO PCT/US2015/041709 patent/WO2016014778A1/en not_active Ceased
- 2015-07-23 JP JP2017504104A patent/JP6453441B2/ja not_active Expired - Fee Related
- 2015-07-23 EP EP15825076.1A patent/EP3171870B1/en not_active Not-in-force
- 2015-07-23 US US15/328,838 patent/US20170209434A1/en not_active Abandoned
-
2018
- 2018-08-20 US US16/105,479 patent/US10434100B2/en active Active
- 2018-12-12 JP JP2018232414A patent/JP6862404B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523178A5 (cg-RX-API-DMAC7.html) | ||
| PH12022550783A1 (en) | Antiviral heterocyclic compounds | |
| EA202090514A1 (ru) | Противовирусное средство против гепатита в | |
| PH12021551116A1 (en) | Functionalized heterocycles as antiviral agents | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| MX384836B (es) | Agentes antivirales contra la hepatitis b | |
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| JP2017523187A5 (cg-RX-API-DMAC7.html) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| EA201200890A1 (ru) | Комбинированная терапия hcv | |
| JP2014504643A5 (cg-RX-API-DMAC7.html) | ||
| JP2015505564A5 (cg-RX-API-DMAC7.html) | ||
| RU2013155509A (ru) | Применение ингибирования катепсина к для лечения и/или профилактики легочной гипертензии и/или сердечной недостаточности | |
| JO3434B1 (ar) | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| EA025948B1 (ru) | КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR | |
| EA202191548A1 (ru) | Ингибиторы плазменного калликреина человека | |
| JP2011518168A5 (cg-RX-API-DMAC7.html) | ||
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| RU2013145869A (ru) | КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ | |
| EA201170484A1 (ru) | Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| RU2011101771A (ru) | Педиатрические композиции для лечения рассеянного склероза | |
| JP2015526504A5 (cg-RX-API-DMAC7.html) | ||
| JP2019524889A5 (cg-RX-API-DMAC7.html) |